WHO issues its first hepatitis B treatment guidelines
WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries. Worldwide, some 240 million people have chronic hepatitis B virus with the highest rates of infection in Africa and Asia. People with chronic hepatitis B infection are at increased risk of dying from cirrhosis and liver cancer.
Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Tavakol, Saeed Samarghandian, Masoud Najafi
Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Na Fu, Huijuan Du, Dongdong Li, Yu Lu, Wencong Li, Yang Wang, Lingbo Kong, Jinghua Du, Suxian Zhao, Weiguang Ren, Fang Han, Rongqi Wang, Yuguo Zhang, Yuemin Nan
Publication date: 1 September 2020Source: Life Sciences, Volume 256Author(s): Neda Khalili, Masoud Nouri-Vaskeh, Zahra Hasanpour Segherlou, Amir Baghbanzadeh, Monireh Halimi, Haleh Rezaee, Behzad Baradaran
Publication date: Available online 2 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Ping Huang, Guanchun Wang, Zhaohong Wang, Cancan Zhang, Fengmian Wang, Xiaoxiao Cui, Sini Guo, Wei Huang, Rong Zhang, Deyue Yan
Publication date: 24 September 2020Source: Inorganica Chimica Acta, Volume 510Author(s): Thankaraj Salammal Sheena, Rajakumaran Dhivya, Venkatesan Rajiu, K. Jeganathan, Mallayan Palaniandavar, Ganesan Mathan, Mohammad Abdulkader Akbarsha
CONCLUSIONS: The introduction of spacer sequence between chelator and BBN(7-14) led to improved bidistribution. Analogue with tri-Gly spacer is the more promising radiopeptide for targeting GRP receptor than Ser conjugate. Therefore, these analogs can be considered as a candidate for the identification of bombesin-positive tumors. PMID: 32497000 [PubMed - as supplied by publisher]
Authors: Ao H, Li Y, Li H, Wang Y, Han M, Guo Y, Shi R, Yue F, Wang X Abstract Hydroxy genkwanin (HGK), a flavonoid compound from natural resources, showed good inhibition against the growth of breast tumor cells. However, the poor solubility restricted the further study and the in vivo drug delivery of HGK. We prepared HGK nanosuspensions by antisolvent precipitation method and investigated their characterization, stability, hemolysis probability, release behavior in vitro, antitumor activity in vitro and in vivo, and preliminary safety through acute toxicity experiments. The resultant HGK nano...
Authors: Zhang X, Ren X, Tang J, Wang J, Zhang X, He P, Yao C, Bian W, Sun L Abstract Multidrug resistance (MDR) of cancer cells is a significant challenge in chemotherapy, highlighting the urgent medical need for simple and reproducible strategies to reverse this process. Here, we report the development of an active tumor-targeting and redox-responsive nanoplatform (PA-ss-NP) using hyaluronic acid-g-cystamine dihydrochloride-poly-ε-(benzyloxycarbonyl)-L-lysine (HA-ss-PLLZ) to co-deliver paclitaxel (PTX) and apatinib (APA) for effective reversal of MDR. This smart nanoplatform specifically bound to CD44 rec...
This article was originally published on The Conversation. Read the original article. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Discussion It is estimated that 180 million people worldwide are infected with Hepatitis C (HCV) which includes ~11 million children. In the United States it is estimated that there were 30,500 acute HCV cases in 2014, and 2.7-3.9 million people with chronic HCV. Many infections are not identified. It is estimated that “…only 5-15% of HCV-infected children in the United States are identified.” Problems associated with HCV include acute hepatitis (including fever, malaise, dark-urine, abdominal pain, jaundice, appetite loss, nausea, emesis, clay-colored stools), acute fulminant hepatitis (not common in c...